Stereoactive Ablative Radiotherpay
SABR is now routinely commissioned in the EofE for selected patients with oligometastases. If there is a patient with up to 3 metastases following successful treatment of the primary cancer then they may be suitable for SABR to these sites of oligometastatic disease. Inclusion and exclusion criteria are available.